Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019)
Forte Biosciences (FBRX) reported EBITDA Margin of -24555.56% for Q4 2019, up 185488.89 percentage points from -210044.44% a year earlier but down 19444.44 percentage points from the prior quarter.
Powered by 
Analysis
Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019) Analysis & Trends
For FY2019, Forte Biosciences posted EBITDA Margin of -11258.33%, down 11007.57 percentage points from FY2018.
- EBITDA Margin has a three-year change of +52894.73 percentage points (FY2016 to FY2019).
- By year, EBITDA Margin came in at -250.77% in FY2018 (+90812.65 pp), -91063.41% in FY2017 (-26910.35 pp) and -64153.06% in FY2016.
- Five-year quarterly EBITDA Margin spans a low of -210044.44% in Q4 2018 and a high of 9.03% in Q3 2018.
- Year over year, EBITDA Margin gained in three of the last seven quarters, with an average year-over-year change of +30123.97 percentage points.
- Per Business Quant data, the three quarters before Q4 2019 came in at -5111.11% (Q3 2019), -4577.78% (Q2 2019) and -185055.56% (Q1 2019).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Forte Biosciences | 1.58 Bn | 1.38 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -24,555.56% |
| Sep 30, 2019 | -5,111.11% |
| Jun 30, 2019 | -4,577.78% |
| Mar 31, 2019 | -185,055.56% |
| Dec 31, 2018 | -210,044.44% |
| Sep 30, 2018 | 9.03% |
| Jun 30, 2018 | -168,888.89% |
| Mar 31, 2018 | -141,677.78% |
| Dec 31, 2017 | -105,910.00% |
| Sep 30, 2017 | -96,680.00% |
| Jun 30, 2017 | -85,900.00% |
API Access
Forte Biosciences EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "FBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();